Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression
- 12 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 8 (9), 1215-1227
- https://doi.org/10.1158/2326-6066.CIR-19-0371
Abstract
Androgen receptor (AR) antagonism increases overall survival in prostate cancer; however, treatment failure leads to tumor progression and patient mortality. The effect of AR modulation on AR(+) nontumor cells that participate in the resistance to AR antagonism is poorly understood. Tumor-infiltrating myeloid cells, including macrophages and myeloid-derived suppressor cells (MDSC), express AR and promote prostate cancer progression. We investigated how AR antagonism affects myeloid cell function and metabolism in an AR-independent murine colon tumor model. Systemic blockade of AR with enzalutamide resulted in increased MC-38 tumor growth in vivo even when AR was knocked out of MC-38 tumor cells. MC-38 tumor growth was also increased when immunocompetent, but not immuno-deficient, mice were coinjected with tumor cells and MDSCs treated with enzalutamide or lacking AR, suggesting that AR regulated the ability of MDSCs to suppress adaptive immunity. Myeloid AR-knockout male mice also displayed increased growth of TRAMP C2 prostate tumors when compared with wild type. Inhibition of AR signaling suppressed mitochondrial respiration in myeloid cells via MPC/AMPK signaling pathways; suppression of mitochondrial respiration increased MDSC tumor-promoting functions. Our work showed that AR regulates a tumor-promoting myeloid cell phenotype and influences myeloid cell metabolism. These findings suggest that tumor resistance to AR antagonism is due, in part, to changes in myeloid cell function and metabolism.Other Versions
Funding Information
- NIH (5P01CA98156)
- Roswell Park Cancer Institute (P30CA016056)
- U.S. Department of Defense (PC131811)
This publication has 41 references indexed in Scilit:
- Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2‐induced STAT3 activationEMBO Molecular Medicine, 2013
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signalingCell Death & Disease, 2013
- A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate CancerCancer Research, 2013
- A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila , and HumansScience, 2012
- The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesisThe EMBO Journal, 2011
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonistsThe Prostate, 2010
- Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription FactorImmunity, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-α expressionJCI Insight, 2009